Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More updates means that he will continue to provide articles in 2019
5 bullish CNAT articles on SA in last 8 days by 5 different authors.
Sorry, wrong board.
Actually 5 bullish SA articles in last 8 days. 5 different authors.
Only down 20% ? You are fortunate in this sector.
Anixa has a prostate diagnostic (CYDY has a diagnostic and PROGnostic with Prostagene) https://ir.anixa.com/press-releases/detail/901/anixa-biosciences-announces-completion-of-pre-sub-meeting
$137 Mill in reservations. Now that they can sell a product, they are taking deposits and orders. No word yet. I guess in early Jan, there will be a conf call.
Tomorrow’s conf call is “to provide a business update. “. This doesn’t sound necessarily positive. I’m not negative, but no .... oomph to the p.r.
I was hoping for a nice announcement, with a conf call detailing the good news the next morning.
This SA article disagrees. Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise $CNAT https://seekingalpha.com/article/4227368
Could this also be an indication that CNAT (funded by Novartis) May be out in the cold ?
Very Good long Seeking Alpha article by PhD. https://seekingalpha.com/article/4227368-conatus-emricasan-nash-cirrhotic-portal-hypertension-overlooked-therapeutic-promise
Price target of $9.54, maybe.
Actually, just a headline.
As your icon would say, “Ex-cellent !”
No. Down 8 cents near the opening
Trading to 6 decimal places ??? So if you buy 10,000 shares, it would make one penny difference.
Trading to 6 decimal places ??? So if you buy 10,000 shares, it would make one penny difference.
You are still wrong.
Wow! And to think that one can *learn* something by actually reading the darn thing. Thanks.
Yes and thank you for that clarification. But there is still the 45 and 79 Mill share forms filed this morning also. Are those ALSO revisions of old Cytodyn filings ?
I wouldn’t say kill, but definitely mute any significant upside. I may sell half of what picked up yesterday. I bought on the presumption of revenues from Prostagene test in foreseeable future. That’s not happening. The company near always issues shares on any good news.
Given past history as a guide, with shares being issued I think we are gonna drop like a rock today.
Wait, 27 Mill shares for Prostagene, another 45 Mill shares, plus up to $200 Mill in offering ? Sounds like they aren’t expecting any licensing deal soon. Or am I misreading this ?
Yes, it may seem like 900 years. ??
Bought a little more today. 10% premium to Friday, but that’s ok.
Yes, but the $1 rule may come back into play at some point. However, in the coming months, RGSE might get back up to $1. RGSE can apply for a 6-month extension but by then a lot of sales will be coming in. We’re good on this point.
The time to invest in MNGA is when they no longer have to dilute, or when they make their first penny in earnings. I don’t think the company is there yet. First half of 2019, I’d guess.
We wouldn’t EXPECT $10 a share. So much has yet to happen before that is possible.
A low price For everything AS THEY STAND NOW. I can imagine a potential BO at much higher levels assuming some things like the acquisition of Prostagene, filing of combo BLA, interim data of pivotal mono trial, approval of prog /diagnostic tests, licensing of prog tests. A LOT has yet to happen. Until licensing there will Be continued Paulson raises.
With 400+ Mill fully diluted shares, $30 is an absurd price even post BLA. $12 Bill ? With Mono ph 3 so far from completion or re-initiation ... no way.
As a shareholder, yes ! After Prostagene purchase in December, the company has maybe 10 employees ? How many salesmen would need to be hired ? How many much larger companies have failed at selling their own drug ? Other companies experiences in this regard are discouraging.
The intraday chart today was not a head and shoulders, but more of a mitten.
12 Mill shares traded in 45 min. Up another 20% ... what a rush !
I heard that a CRL is announced by company, but approval is announced by FDA. Company would likely announce later. Think ... it’s good news.
And 83 cents in cash / share. With patents, Trading below book value
Years ago, My surgeon (who uses DaVinci) said that the thing that would help him the most was to be able to feel tissue. With Senhance he could have that.
7-8 vote, some of the no’s wanted to vote yes, members talked about phase 4, TRVN presentation rocked, some no’s were ... prejudiced ... overall our chances are great compared to other AdCom no votees.
Risk reward is compellingly favorable, but still a lot of risk.
How are you guys confident about PDUFA ? I watched the AdCom. After FDAs lack of preparedness and knowledge evidenced by the AdCom meeting, I wonder if they CAN recognize a good (or bad) drug if the evidence is in front of them. My confidence in the system is shaken.
This will be the 16th day in a row we close over $1. No delisting here.